Who
David Charles Lubner
Director
Company insider
Files Form 4 as: Director, Braveheart Bio; Director, Dyne Therapeutics; Director, Crescent Biopharma; Director, Arcellx; Director, CARGO Therapeutics; Director, Vor Biopharma; Director, POINT Biopharma Global; Director, Disc Medicine.
In numbers
- Trades disclosed
- 132
- Buys
- 2
- Sells
- 10
- Bought
- $2.0M
- Sold
- $3.4M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 25 Mar 2013
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $1000K55,555 at $18.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | BRVE Braveheart BioBiotechnology | SEC FORM 4 Bought | $1000K55,555 at $18.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,152 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,050 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,050 at $0.00 | filing |
| 28 Apr 2026filed 28 Apr 2026 | ArcellxBiotechnology | SEC FORM 4 Code U | —21,659 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,626 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —59,405 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —13,626 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —59,405 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —31,794 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —61,538 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —11,459 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —8,011 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative | SEC FORM 4 Code D | —9,174 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,794 | filing |
| 28 Apr 2026filed 28 Apr 2026 | Arcellxoption or derivative · Biotechnology | SEC FORM 4 Code D | —61,538 | filing |
News
Braveheart Bio (NASDAQ:BRVE) Stock Price Down 7.6% – Here's WhyBRVE · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name David Charles Lubner; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.